Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic
Wednesday, July 16, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: Precision BioSciences has announced promising new preclinical data for its PBGENE-DMD candidate, which shows an increase in dystrophin positive muscle cells across key muscle types. This data suggests that the gene editing approach may effectively target muscle satellite cells. The advancement supports the potential for clinical application in treating Duchenne Muscular Dystrophy.
Price reaction · baseline $4.45 (2025-07-15 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close
+1.6%
Market Sentiment Analysis
POSITIVE FACTORS
New preclinical data shows increased dystrophin positive muscle cells.
Potentially effective editing of muscle satellite cells.
Advancement towards clinical application for Duchenne Muscular Dystrophy.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– New preclinical data for the PBGENE-DMD final clinical candidate demonstrates an increase in dystrophin positive muscle cells across key muscle types, potentially driven by editing of muscle satellite cells – – PBGENE-DMD is a first-in-class in vivo gene editing approach for up to 60% of Duchenne
Frequently Asked Questions
What is PBGENE-DMD?
PBGENE-DMD is a first-in-class in vivo gene editing approach targeting Duchenne Muscular Dystrophy.
What does the new data show?
The new preclinical data indicates an increase in dystrophin positive muscle cells.
How does PBGENE-DMD work?
It potentially drives muscle satellite cell editing to improve muscle cell function.
What is the significance of this data?
It supports the advancement of PBGENE-DMD towards clinical application.